However, we noted great variability and multiple inconsistencies in the patient’s cognitive deficits during hospitalization, and the absence of associated biomarkers of Alzheimer’s disease (tau protein, phosphorylated tau, and beta-amyloid) in corticospinal fluid at the first dosing two years ago. The gene discussed is MAPT; the disease is Alzheimer disease.